Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for COVID-19
Molecular Partners AG - American Depositary Shares (MOLN)
Company Research
Source: GlobeNewswire
Agreement grants global rights of ensovibep to Novartis, who will lead further development and commercialization of the programFinancial terms include milestone payment of CHF150 million to Molecular Partners and 22% royalty on ensovibep sales in relevant territoriesCollaboration will focus on rapidly progressing ensovibep’s availability to COVID-19 patients via expedited regulatory processes ZURICH-SCHLIEREN, Switzerland & CONCORD, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Molecular Partners and Novartis have entered into a license agreement under which Novartis will in-license global rights to ensovibep from Molecular Partners. Ensovibep is a DARPin antiviral therapeutic candidate to treat COVID-19, which recently reported positive topline data from the
Show less
Read more
Impact Snapshot
Event Time:
MOLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MOLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MOLN alerts
High impacting Molecular Partners AG - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MOLN
News
- Life Science Cares Launches in Switzerland [Yahoo! Finance]Yahoo! Finance
- Life Science Cares Launches in SwitzerlandGlobeNewswire
- We Think Molecular Partners (VTX:MOLN) Needs To Drive Business Growth Carefully [Yahoo! Finance]Yahoo! Finance
- Molecular Partners Announces All Board Proposals Approved at the Annual General MeetingGlobeNewswire
- Molecular Partners Publishes Invitation to Annual General Meeting 2024GlobeNewswire
MOLN
Sec Filings
- 3/26/24 - Form 6-K
- 3/14/24 - Form 20-F
- MOLN's page on the SEC website